Work

Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach

Year: 2023

Type: review

Source: Nature Reviews Gastroenterology & Hepatology

DOI: 10.1038/s41575-023-00796-x

Authors: Paul N. Brennan, Ahmed M. Elsharkawy, Timothy J. Kendall, Rohit Loomba, Derek A. Mann, Jonathan A. Fallowfield

Institutions: University of Dundee, University of Edinburgh, University Hospitals Birmingham NHS Foundation Trust, NIHR Birmingham Liver Biomedical Research Unit, NIHR Birmingham Biomedical Research Centre, University of California San Diego, Koç University, Newcastle University

Language: English

Topic: Liver Disease Diagnosis and Treatment

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Cancer Research UK, National Institutes of Health, Medical Research Council, National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Advancing Translational Sciences

Awards: G1027702206, A Cardiovascular-NASH disease nexus: Common Mechanisms and Treatments?, MICA: Molecular drivers of fibrosis at the hepatic epithelial-mesenchymal barrier, Non-invasive screening of diabetics for advanced fibrosis due to NAFLD, Ancillary Studies of NAFLD and NASH in HIV infected Adults, G6579111958, QUS Technology for Diagnosis and Grading of Hepatic Steatosis in NAFLD, UC San Diego Clinical and Translational Research Institute, San Diego Digestive Diseases Research Center, Clinical Research on Nonalcoholic Fatty Liver Disease, San Diego Cirrhosis Clinical Research Network

OpenAlex ID: W4379142260

FWCI: 2.074

Cites: 122

Cited by: 69

Related to: 10